Figure 7.

Activation of JNK and ERK upon the exposure of Cas III-ia. A) Total cell lysated from control cell and treated cells with Cas III-ia (5, 10, 15 and 20 μg/ml). were inmmuno-blot for detection of phospho-JNK, total JNK, phospho-ERK, total ERK, phosphor-c-jun and total c-jun. The figures shown are representative of at least three different experiments for each experimental condition. B) Effect of SP600125 (inhibitor de JNK) and PD98059 (inhibitor of ERK) on cell viability of 24 h Cas III-ia treated cells. The cell viability were determined by MTT assay in control cell and treated cells with Cas III-ia (5, 10, 15 and 20 μg/ml), Cas III-ia (5, 10, 15 and 20 μg/ml) + 25μM SP600125 and Cas III-ia (5, 10, 15 and 20 μg/ml) + 25μM PD98059. Data representative of means ± SD (*P ≤ 0.05, **P ≤ 0.01 and ***P ≤ 0.001) of three independent experiments.

Trejo-Solís et al. BMC Cancer 2012 12:156   doi:10.1186/1471-2407-12-156
Download authors' original image